Skip to Content

'
Stacy L. Moulder, M.D., M.S.C.I.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Director of the Breast Center, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

  • Early Drug Development
  • Clinical Trial Design
  • Determining Pathways of Drug Resistance in Breast Cancer

Click here for the most up-to-date list of Dr. Moulder's publications.

Office Address

The University of Texas MD Anderson Cancer Center
Breast Medical Oncology - Unit 1354
P.O. Box 301438
Houston, TX 77230-1439
Phone: 713-792-2817
Fax: 713-794-4385

Education & Training

Degree-Granting Education

2002 Vanderbilt University, Nashville, TN, MS, Masters of Science in Clinical Investigation
1995 University of Mississippi School of Medicine, Jackson, MS, MD, Medicine
1990 Mississippi State University, Jackson, MS, BS, Graduated Cum Laude, Chemistry

Postgraduate Training

7/1998-6/2001 Clinical Fellowship, Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN
7/1995-6/1998 Internship and Residency, Internal Medicine, University of Mississippi Medical Center, Jackson, MS

Board Certifications

11/2002 American Board of Internal Medicine, Medical Oncology
8/1998 American Board of Internal Medicine

Experience/Service

Administrative Appointments/Responsibilities

Chair, Clinical Research Committee, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009-2011

Other Appointments/Responsibilities

Planning Committee, Translational Breast Cancer Research Consortium, Houston, TX, 2008-present
Planning Committee, American College of Surgeons Oncology Group, Houston, TX, 2008-2009

Institutional Committee Activities

Planning Committee, Breast Cancer Clinical Research Seminar, 8/2009-present
Chair, Clinical Research Committee, 2008-2011
Member, Internal Review Board, 2008-2011
Chair, Breast Cancer Serum/DNA Bank Oversight Committee, 2008-2009
Member, Breast Cancer Tumor Bank Committee, Department of Breast Medical Oncology, 2007-2008
Member, Serum Bank Committee, Department of Breast Medical Oncology, 2006-present
Member, Clinical Research Committee, 2006-2008

Honors and Awards

2002 Career Development Award, American Society of Clinical Oncology
2001 Fellowship Award, American Association for Cancer Research
2001 Merit Award, American Society of Clinical Oncology
2001 Star Fellow Award, Vanderbilt Hematology Oncology
2001 Trainee Travel Award, American Society of Clinical Investigation
2000 Star Fellow Award, Vanderbilt Hematology Oncology
1998-2002 Harry Joyce Fellowship, Vanderbilt University Medical Center
1994 Associated Student Body Vice President, University of Mississippi School of Medicine
1992 Medical Student Research Fellowship, University of Mississippi Medical Center

Selected Publications

Invited Articles

1. Moulder SL. Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials. Clin Breast Cancer 10:S30-40, 9/2010. PMID: 20805063.
2. Moulder SL, Craft BS, Hortobagyi GN. Inhibition of receptor tyrosine kinases in combination with chemotherapy for the treatment of breast cancer. Anticancer Agents Med Chem 8(5):481-7, 6/2008. PMID: 18537531.
3. Moulder SL. Ixabepilone for the treatment of taxane-refractory breast cancer. Future Oncol 4(3):333-40, 6/2008. PMID: 18518758.
4. Moulder S, Hortobagyi GN. Advances in the treatment of breast cancer. Clin Pharmacol Ther 83(1):26-36, 1/2008. PMID: 18091763.
5. Craft BS, Hortobagyi GN, Moulder SL.. Adjuvant biologic therapy for breast cancer. Cancer J 13(3):156-61, 6/2007. PMID: 17620764.
6. Arteaga CL, Moulder SL, Yakes FM. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol 29(3 Suppl 11):4-10, 6/2002. PMID: 12138392.
7. Moulder SL, Roth BJ. Systemic chemotherapy for urothelial transitional cell carcinoma: An overview of toxicity. Semin Urol Oncol 19(3):194-201, 8/2001. PMID: 11561987.

Last updated: 8/1/2013